These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10389868)

  • 1. Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer.
    Takeda A; Nakajima K; Shimada H; Imaseki H; Takayama W; Hayashi H; Suzuki T; Ochiai T; Isono K
    J Surg Oncol; 1999 Jun; 71(2):112-6. PubMed ID: 10389868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
    Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Iwasaki K; Makino H; Natsume T; Kouno T; Kondo S; Suzuki T; Ochiai T; Isono K
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):879-83. PubMed ID: 10897215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer.
    Shimada H; Okazumi S; Takeda A; Nabeya Y; Matsubara H; Funami Y; Hayashi H; Gunji Y; Suzuki T; Ochiai T
    Surg Today; 2001; 31(7):591-6. PubMed ID: 11495153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of p53 protein, Bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumors.
    Itaya M; Yoshimoto J; Kojima K; Futagawa S
    Oncol Rep; 1999; 6(3):675-82. PubMed ID: 10203614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer.
    Hashimoto Y; Ueda K; Minami K; Watatani M
    Int J Clin Oncol; 2001 Apr; 6(2):90-6. PubMed ID: 11706756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.
    Hammel P; Boissier B; Chaumette MT; Piedbois P; Rotman N; Kouyoumdjian JC; Lubin R; Delchier JC; Soussi T
    Gut; 1997 Mar; 40(3):356-61. PubMed ID: 9135525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
    Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
    Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer.
    Ji WB; Um JW; Ryu JS; Hong KD; Kim JS; Min BW; Joung SY; Lee JH; Kim YS
    Anticancer Res; 2017 May; 37(5):2679-2682. PubMed ID: 28476844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of the histoculture drug response assay.
    Furukawa T; Kubota T; Hoffman RM
    Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection.
    Takeda A; Shimada H; Nakajima K; Yoshimura S; Suzuki T; Asano T; Ochiai T; Isono K
    Int J Clin Oncol; 2001 Feb; 6(1):45-9. PubMed ID: 11706527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies against p53 are associated with poor prognosis of colorectal cancer.
    Houbiers JG; van der Burg SH; van de Watering LM; Tollenaar RA; Brand A; van de Velde CJ; Melief CJ
    Br J Cancer; 1995 Sep; 72(3):637-41. PubMed ID: 7669574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of wild-type and mutant E-cadherin on cell proliferation and responsiveness to the chemotherapeutic agents cisplatin, etoposide, and 5-fluorouracil.
    Fricke E; Hermannstädter C; Keller G; Fuchs M; Brunner I; Busch R; Höfler H; Becker KF; Luber B
    Oncology; 2004; 66(2):150-9. PubMed ID: 15138368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay.
    Yamaue H; Tanimura H; Nakamori M; Noguchi K; Iwahashi M; Tani M; Hotta T; Murakami K; Ishimoto K
    Dis Colon Rectum; 1996 Apr; 39(4):416-22. PubMed ID: 8878502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of serum p53 antibodies in mucosal colorectal cancer and negative conversion after endoscopic resection.
    Takeda A; Nakajima K; Shimada H; Imazeki H; Takayama W; Hayashi H; Yoshimura S; Suzuki T; Ochiai T; Isono K
    J Clin Gastroenterol; 1999 Mar; 28(2):153-4. PubMed ID: 10078825
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
    Cho YB; Lee WY; Song SY; Choi SH; Shin HJ; Ahn KD; Lee JM; Kim HC; Yun SH; Chun HK
    Eur J Surg Oncol; 2009 Sep; 35(9):951-6. PubMed ID: 19181477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
    Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
    Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
    Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
    Nabeya Y; Loganzo F; Maslak P; Lai L; de Oliveira AR; Schwartz GK; Blundell ML; Altorki NK; Kelsen DP; Albino AP
    Int J Cancer; 1995 Feb; 64(1):37-46. PubMed ID: 7665247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer.
    Hammel P; Leroy-Viard K; Chaumette MT; Villaudy J; Falzone MC; Rouillard D; Hamelin R; Boissier B; Remvikos Y
    Int J Cancer; 1999 May; 81(5):712-8. PubMed ID: 10328221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.